The present study suggests that targeting the PD-1 and TIGIT signaling pathways enhances the response to neoantigen vaccines in pancreatic cancer, highlighting the potential synergy of these therapies in pancreatic cancer. The gene discussed is TIGIT; the disease is pancreatic neoplasm.